Medtronic
(NYSE: MDT)
announced today that it entered into a definitive agreement to acquire Scientia Vascular in a deal valued at $550 million.
Salt Lake City, Utah–based Scientia Vascular develops access products for treating complex neurovascular conditions. Its portfolio features guidewires and catheters that Medtronic can seamlessly integrate into its existing suite of neurovascular products. That includes microwires and microcatheters designed to make neurovascular cases easier, faster and safer.
Scientia’s novel access platform addresses the challenges of the cerebral vasculature by improving navigability through complex anatomy to simplify neurovascular procedures. Medtronic said the technology enables faster and more reliable access to improve procedural efficiency.
The medtech giant said the acquisition strengthens its ability to support physicians across the full procedural workflow in stroke treatment.
With the acquisition, Medtronic becomes the latest big-name medtech company to make a neurovascular play by acquiring stroke-treating technology. It follows the likes of Boston Scientific, which agreed to acquire Penumbra this year, and Stryker, which bought Inari Medical a year ago. The deal also marks the second major acquisition of 2026 for Medtronic, which acquired CathWorks in February.
The deal is valued at $550 million, subject to customary adjustments. It also includes potential undisclosed earn-out and milestone payments post-acquisition. Scientia currently operates with approximately 310 employees. Medtronic expects to close the deal in the first half of its fiscal 2027 (which runs from May 1, 2026, to Oct. 31, 2026). It anticipates a minimally dilutive impact to adjusted EPS in fiscal 2027, with an accretive impact thereafter.
Commentary from Medtronic and Scientia officials
Linnea Burman, SVP and president of Medtronic’s Neurovascular business, said:
“Medtronic is thrilled to acquire Scientia to accelerate meaningful innovation in neurovascular care. This acquisition positions Medtronic with a full suite of products. It builds a strong foundation for Medtronic and supports procedures across both hemorrhagic and acute ischemic stroke. Medtronic’s best-in-class therapies, combined with Scientia’s leading access portfolio, will be incredibly powerful. With 12 million people globally suffering from stroke each year, we look forward to contributing to better patient outcomes around the world.”
Rick Randall, CEO, Scientia, said:
“As a company committed to improving patients’ lives, we are humbled and excited for what’s ahead. Scientia has developed critical technology that has been embraced by physicians. This deal allows us to take our engineering into disease states globally and positions Medtronic with a comprehensive portfolio and complete guidewire line. With the size and scale of Medtronic, the opportunity to treat more patients and drive more impact is truly exciting.”
The analysts’ take
Needham analyst Mike Matson has maintained a “Buy” rating for Medtronic following the announcement of the acquisition.
Matson said he and fellow analysts are “glad to see” Medtronic increasingly pursue tuck-in acquisitions.
“We believe that the deal brings [Medtronic] additional products that complement its existing Neurovascular business and believe that these products may experience faster growth under [Medtronic]s ownership given its larger sales force and international presence,” Matson wrote. “Given management’s prior comments, we expect to see [Medtronic] continue to pursue additional tuck-in acquisitions.
